ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
In a deal crafted to mitigate the risk associated with compounds in development, Actelion has paid $13 million for an option to acquire Trophos. If Trophos’ lead compound, olesoxime, produces positive Phase III results in treating amyotrophic lateral sclerosis, Actelion will pay between $160 million and $250 million for the Marseille, France-based biotech firm. Olesoxime is a cholesterol-oxime compound identified by Trophos’ neuronal cell-screening platform. Trophos also has agreed to give Actelion access to its central nervous system assay technology and compound library.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter